Program
atigotatug
Also written as “BMS-986489 (Atigotatug+Nivolumab)” and “BMS-986489”.
Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.
Furthest: phase 3, since Oct 16, 20242 company-led studies, 1 open or runningNext primary completion: Aug 17, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 21 open or running | phase 3since Oct 16, 2024 | Oct 16, 2024 | Aug 17, 2027phase 3 · NCT06646276 |
- Named in Bristol-Myers Squibb’s own pipeline as
atigotatug
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2024First study: phase 3 study in Small Cell Lung CarcinomaFirst studyNCT06646276 · 530 planned · United States, Argentina, Australia and more
- Jan 24, 2025Phase 1 study in Small Cell Lung CarcinomaNCT06799286 · 10 enrolled · China
Ahead
- Aug 17, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06646276
TargetBeta
“A fixed-dose combination formulation composed of atigotatug, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the ganglioside fucosyl-GM1, and nivolumab, a human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell surface rec…”NCIt, read by Claude
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06799286Small Cell Lung Carcinoma · China | 1 | Completed | Sep 9, 2026 | 10 |
| NCT06646276Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Recruiting | Aug 17, 2027 | 530 |
How it is read
Names in the registry
- “BMS-986489 (Atigotatug+Nivolumab)”, 1 entry
- “BMS-986489”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.